Skip to end of metadata
Go to start of metadata

2016

March

Prostate Cancer Imaging with Novel PET Tracers. Lindenberg L, Choyke P, Dahut W. Curr Urol Rep. 2016 Mar;17(3):18. doi: 10.1007/s11934-016-0575-5.

Pharmacodynamic Response of the MET/HGF-Receptor to Small Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. Srivastava AK, Hollingshead MG, Weiner J, Navas T, Evrard YA, Khin SA, Ji JJ, Zhang Y, Borgel S, Pfister TD, Kinders R, Bottaro DP, Linehan WM, Tomaszewski JE, Doroshow JH, Parchment RE. Clin Cancer Res. 2016 Mar 21. pii: clincanres.2323.2015.

Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ. Cell Rep. 2016 Mar 15;14(10):2476-89. doi: 10.1016/j.celrep.2016.02.024.

Metabolic syndrome in relation to Barrett's esophagus and esophageal adenocarcinoma: Results from a large population-based case-control study in the Clinical Practice Research Datalink. Drahos J, Li L, Jick SS, Cook MB. Cancer Epidemiol. 2016 Mar 9;42:9-14. doi: 10.1016/j.canep.2016.02.008.

Is birthweight associated with total and aggressive/lethal prostate cancer risks? A systematic review and meta-analysis. Zhou CK, Sutcliffe S, Welsh J, Mackinnon K, Kuh D, Hardy R, Cook MB. Br J Cancer. 2016 Mar 1. doi: 10.1038/bjc.2016.38

A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JA, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak MN, Price AJ, Roobol M, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Zeigler RG, Key TJ, Allen NE. Cancer Res. 2016 Feb 26. pii: canres.1551.2015. 

MicroRNA Profiles of Barrett's Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium. Drahos J, Schwameis K, Orzolek LD, Hao H, Birner P, Taylor PR, Pfeiffer RM, Schoppmann SF, Cook MB. Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):429-37. doi: 10.1158/1055-9965.EPI-15-0161

Near infrared photoimmunotherapy with an anti-mesothelin antibody. Nagaya T, Nakamura Y, Sato K, Zhang YF, Ni M, Choyke PL, Ho M, Kobayashi H. Oncotarget. 2016 Mar 10. doi: 10.18632/oncotarget.8025

Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine. Bouchelouche K, Choyke PL. Curr Opin Oncol. 2016 Mar 10.

The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men. Kongnyuy M, Sidana A, George AK, Muthigi A, Iyer A, Fascelli M, Kadakia M, Frye TP, Ho R, Mertan F, Minhaj Siddiqui M, Su D, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA. Urol Oncol. 2016 Feb 20. pii: S1078-1439(15)00614-6. doi: 10.1016/j.urolonc.2015.12.018

Prostate Cancer Imaging with Novel PET Tracers. Lindenberg L, Choyke P, Dahut W. Curr Urol Rep. 2016 Mar;17(3):18. doi: 10.1007/s11934-016-0575-5.

Advanced imaging techniques in genitourinary cancers. Turkbey B, Choyke PL. Urol Oncol. 2016 Mar;34(3):123. doi: 10.1016/j.urolonc.2015.11.024.

Differentiating Transition Zone Cancers From Benign Prostatic Hyperplasia by Quantitative Multiparametric Magnetic Resonance Imaging. Elbuluk O, Muradyan N, Shih J, Bernardo M, Sankineni S, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B. J Comput Assist Tomogr. 2016 Mar-Apr;40(2):218-24. doi: 10.1097/RCT.0000000000000353.

Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: biomarker for treatment selection exclusion or inclusion? Leibrand CR, Price DK, Figg WD. Cancer Biol Ther. 2016 Mar 17:0. 

The canSAR data hub for drug discovery. Chau CH, O'Keefe BR, Figg WD. Lancet Oncol. 2016 Mar;17(3):286. doi: 10.1016/S1470-2045(16)00095-4

Building a hit list for the fight against metastatic castration resistant prostate cancer. Strope JD, Price DK, Figg WD. Cancer Biol Ther. 2016 Mar 3;17(3):231-232.

UGT genotyping in belinostat dosing. Goey AK, Figg WD. Pharmacol Res. 2016 Mar;105:22-7. doi: 10.1016/j.phrs.2016.01.002

The evolving role of immunotherapy in prostate cancer. Cordes LM, Gulley JL, Madan RA. Curr Opin Oncol. 2016 Mar 14.

Prospects for the future of prostate cancer vaccines. Madan RA, Gulley JLExpert Rev Vaccines. 2016 Mar;15(3):271-4. doi: 10.1586/14760584.2015.1118348.

Therapeutic vaccines for prostate cancer: recent advances and future directions. Strauss J, Madan RA. Expert Rev Vaccines. 2016 Mar 7:1-8. 

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel E, Nelson PS, Taplin ME, Balk SP, Cai C. Clin Cancer Res. 2016 Mar 2. pii: clincanres.2309.2015.

Quantitative Multiparametric MRI Features and PTEN Expression of Peripheral Zone Prostate Cancer: A Pilot Study. McCann SM, Jiang Y, Fan X, Wang J, Antic T, Prior F, VanderWeele D, Oto A. AJR Am J Roentgenol. 2016 Mar;206(3):559-65. doi: 10.2214/AJR.15.14967.


February

Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. Cherkasova E, Scrivani C, Doh S, Weisman Q, Takahashi Y, Harashima N, Yokoyama H, Srinivasan R, Linehan WM, Lerman MI, Childs RW. Cancer Res. 2016 Feb 9. pii: canres.3139.2015.

Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, Zukiwski A, Wang D, Chen CS, Bottaro D, Ecroyd H, Lebedyeva IO, Dent P. Oncotarget. 2016 Feb 12. doi: 10.18632/oncotarget.7349

Stable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK Cells. Chu C, Bottaro DP, Betenbaugh MJ, Shiloach J. PLoS One. 2016 Feb 5;11(2):e0148075. doi: 10.1371/journal.pone.0148075.

Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study. Zhou CK, Levine PH, Cleary SD, Hoffman HJ, Graubard BI, Cook MB. Am J Epidemiol. 2016 Feb 1;183(3):210-7. doi: 10.1093/aje/kwv190.

Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy. Sato K, Watanabe R, Hanaoka H, Nakajima T, Choyke PL, Kobayashi H. Oncotarget. 2016 Feb 13. doi: 10.18632/oncotarget.7365.

MR imaging biomarkers for evaluating therapeutic effects shortly after near infrared photoimmunotherapy. Nakamura Y, Bernardo M, Nagaya T, Sato K, Harada T, Choyke PL, Kobayashi H. Oncotarget. 2016 Feb 12. doi: 10.18632/oncotarget.7357.

Prostate Cancer Diagnosis on repeat MRI-TRUS Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling. Chelluri R, Kilchevsky A, George AK, Sidana A, Frye TP, Su D, Fascelli M, Ho R, Abboud SF, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA. J Urol. 2016 Feb 12. pii: S0022-5347(16)00327-X. doi: 10.1016/j.juro.2016.02.066

Evaluating the Role of mpMRI in Prostate Cancer Assessment. Mertan FV, Berman R, Szajek K, Pinto PA, Choyke PL, Turkbey B. Expert Rev Med Devices. 2016 Feb;13(2):129-41. doi: 10.1586/17434440.2016.1134311.

Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population. Fascelli M, Rais-Bahrami S, Sankineni S, Brown AM, George AK, Ho R, Frye T, Kilchevsky A, Chelluri R, Abboud S, Siddiqui MM, Merino MJ, Wood BJ, Choyke PL, Pinto PA, Turkbey B. Urology. 2016 Feb;88:125-34. doi: 10.1016/j.urology.2015.09.035

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2170-5. doi: 10.1073/pnas.1525735113

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors. Woodford MR, Truman AW, Dunn DM, Jensen SM, Cotran R, Bullard R, Abouelleil M, Beebe K, Wolfgeher D, Wierzbicki S, Post DE, Caza T, Tsutsumi S, Panaretou B, Kron SJ, Trepel JB, Landas S, Prodromou C, Shapiro O, Stetler-Stevenson WG, Bourboulia D, Neckers L, Bratslavsky G, Mollapour M. Cell Rep. 2016 Feb 2;14(4):872-84. doi: 10.1016/j.celrep.2015.12.084.

Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, Greiner JW. Cancer Immunol Res. 2016 Feb 26. pii: canimm.0176.2015.

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL- 15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, Schlom J, Hodge JW. Oncotarget. 2016 Feb 18. doi: 10.18632/oncotarget.7470

Prostate Imaging Reporting and Data System (PI-RADS), Version 2: A Critical Look. Rosenkrantz AB, Oto A, Turkbey B, Westphalen AC. AJR Am J Roentgenol. 2016 Feb 25:1-5.


January

Prospective Study Evaluating Na18F-Positron Emission Tomography/Computed Tomography (NaF-PET/CT) in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL. J Nucl Med. 2016 Jan 21. pii: jnumed.115.166512.

Phase II Trial of Docetaxel, Bevacizumab, Lenalidomide, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer. Madan RA, Karzai FH, Ning YM, Adesunloye BA, Huang X, Harold N, Couvillon A, Chun G, Cordes L, Sissung T, Beedie SL, Dawson NA, Theoret MR, McLeod DG, Rosner I, Trepel JB, Lee MJ, Tomita Y, Lee S, Steinberg SM, Arlen PM, Gulley JL, Figg WD, Dahut WL. BJU Int. 2016 Jan 18. doi: 10.1111/bju.13412.

Prostate Cancer Susceptibility in Men of African Ancestry at 8q24. Han Y, Rand KA, Hazelett DJ, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Schumacher FR, Berndt SI, Wang Z, Xu J, Rohland N, Reich D, Tandon A, Pasaniuc B, Allen A, Quinque D, Mallick S, Notani D, Rosenfeld MG, Jayani RS, Kolb S, Gapstur SM, Stevens VL, Pettaway CA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, John EM, Murphy AB, Signorello LB, Carpten J, Leske MC, Wu SY, Hennis AJ, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Witte JS, Casey G, Lubwama A, Pooler LC, Sheng X, Coetzee GA, Cook MB, Chanock SJ, Stram DO, Watya S, Blot WJ, Conti DV, Henderson BE, Haiman CA. J Natl Cancer Inst. 2016 Jan 27;108(7). pii: djv431. doi: 10.1093/jnci/djv431

PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study. Turkbey B, Lindenberg ML, Adler S, Kurdziel KA, McKinney YL, Weaver J, Vocke CD, Anver M, Bratslavsky G, Eclarinal P, Kwarteng G, Lin FI, Yaqub-Ogun N, Merino MJ, Marston Linehan W, Choyke PL, Metwalli AR. Abdom Radiol (NY). 2016 Jan;41(1):109-18. doi: 10.1007/s00261-015-0599-1.

Reproducibility of Multiparametric Magnetic Resonance Imaging and Fusion Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort. Rastinehad AR, Abboud SF, George AK, Frye TP, Ho R, Chelluri R, Fascelli M, Shih J, Villani R, Ben-Levi E, Yaskiv O, Turkbey B, Choyke PL, Merino MJ, Wood BJ, Pinto PA. J Urol. 2016 Jan 23. pii: S0022-5347(16)00129-4. doi: 10.1016/j.juro.2015.12.102

Prospective Study Evaluating Na18F-Positron Emission Tomography/Computed Tomography (NaF-PET/CT) in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL. J Nucl Med. 2016 Jan 21. pii: jnumed.115.166512.

Resisting Resistance: Establishing new treatment options for CRPC patients. Beedie S, Figg WD. Cancer Biol Ther. 2016 Jan 30:0. 

Using Epigenetic Therapy to Overcome Chemotherapy Resistance. Strauss J, Figg WD. Anticancer Res. 2016 Jan;36(1):1-4.

Hsp90 in Cancer: Transcriptional Roles in the Nucleus. Calderwood SK, Neckers L. Adv Cancer Res. 2016;129:89-106. doi: 10.1016/bs.acr.2015.08.002.

Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors. Woodford MR, Dunn D, Miller JB, Jamal S, Neckers L, Mollapour M. Adv Cancer Res. 2016;129:31-50. doi: 10.1016/bs.acr.2015.09.002.

Last updated by Sowalsky, Adam (NIH/NCI) [E] on Mar 24, 2016